Molgramostim

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Molgramostim
Accession Number
DB12525
Type
Biotech
Groups
Investigational
Biologic Classification
Protein Based Therapies
Other protein based therapies
Description

Molgramostim has been used in trials studying the treatment of Bronchiectasis, Cystic Fibrosis, Pulmonary Alveolar Proteinosis, Acute Respiratory Distress Syndrome, and Autoimmune Pulmonary Alveolar Proteinosis.

Protein chemical formula
Not Available
Protein average weight
Not Available
Sequences
Not Available
Synonyms
Not Available
Categories
UNII
B321AL142J
CAS number
99283-10-0

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Molgramostim.Approved
AcetyldigoxinAcetyldigoxin may decrease the cardiotoxic activities of Molgramostim.Experimental
BevacizumabBevacizumab may increase the cardiotoxic activities of Molgramostim.Approved, Investigational
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Molgramostim.Approved
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Molgramostim.Approved, Investigational
CymarinCymarin may decrease the cardiotoxic activities of Molgramostim.Experimental
DeslanosideDeslanoside may decrease the cardiotoxic activities of Molgramostim.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Molgramostim.Approved, Investigational
DigoxinDigoxin may decrease the cardiotoxic activities of Molgramostim.Approved
Digoxin Immune Fab (Ovine)Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Molgramostim.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Molgramostim.Approved, Investigational
GitoformateGitoformate may decrease the cardiotoxic activities of Molgramostim.Experimental
Lanatoside CLanatoside C may decrease the cardiotoxic activities of Molgramostim.Experimental
MetildigoxinMetildigoxin may decrease the cardiotoxic activities of Molgramostim.Experimental
OleandrinOleandrin may decrease the cardiotoxic activities of Molgramostim.Experimental, Investigational
OuabainOuabain may decrease the cardiotoxic activities of Molgramostim.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Molgramostim.Approved, Vet Approved
PeruvosidePeruvoside may decrease the cardiotoxic activities of Molgramostim.Experimental
ProscillaridinProscillaridin may decrease the cardiotoxic activities of Molgramostim.Experimental
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Molgramostim.Approved, Investigational
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Substance
347911341
ATC Codes
L03AA03 — Molgramostim

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentAcute Respiratory Distress Syndrome (ARDS) / Bronchiectasis / Cystic Fibrosis (CF) / Pulmonary Alveolar Proteinosis (PAP)1
2, 3RecruitingTreatmentAutoimmune Pulmonary Alveolar Proteinosis1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Taxonomy

Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available

Drug created on October 20, 2016 16:43 / Updated on November 06, 2017 06:46